Coronavirus disease 2019 in immunocompromised patients: a comprehensive review of coronavirus disease 2019 in hematopoietic stem cell recipients

Antoine Lafarge, Asma Mabrouki, Elise Yvin, Swann Bredin, Yannick Binois, Raphael Clere-Jehl, and Elie Azoulay

INTRODUCTION

Immunocompromised patients are notably vulnerable to severe coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2,3]. Solid-organ transplantation recipients, cancer, and hematological malignancy patients more often present with severe COVID-19 diseases, requiring more frequently ICU management, mechanical ventilation. Furthermore, case fatality is higher when compared with the general population [2,3–5].

By September 2021, almost 5000 HSCT recipients with COVID-19 have been reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) (https://www.cibmtr.org/Covid19/Pages/default.aspx#repdata, accessed on 21 September 2021). However, the literature focusing on HSCT recipients and COVID-19 is still limited and gaps in knowledge remain with regards to pathophysiology, clinical features, viral shedding, disease severity, risk factors, and specific therapeutic strategy.

Here we synthesize data from the emerging literature on adult HSCT recipients with COVID-19.

HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS DISPLAY CLASSICAL CORONAVIRUS DISEASE 2019 CLINICAL FEATURES

In the largest published studies focusing on adult HSCT recipients with COVID-19 (Table 1), median age ranged from 35 to 67 years and most of patients were men [2,4,6,7,8,9,10–12].
Consistently with data reported in the general population, the most frequent comorbidities were hypertension, diabetes mellitus, and cardiovascular diseases. In general, immunocompromised patients had more baseline comorbidities than nonimmunocompromised patients, a finding, however, not reported in the cohort from Belsky et al. [2].

HSCT indication, underlying disease status, active graft-versus-host disease (GVHD) and proportions of patients receiving immunosuppressants at the time of COVID-19 diagnosis varied considerably across studies. Median time from HSCT to COVID-19 diagnosis ranged from 14.9 to 25.6 months. Thus, being more than a year from transplantation, most of HSCT patients included in these studies were not receiving immunosuppression at the time of COVID-19. No study reported the time from disease onset to admission in critical care, which has been demonstrated to be a critical prognostic factor in severe patients [13].

As described in the general population, in solid organ transplantation and cancer patients, the most frequent COVID-19-related symptoms reported in HSCT patients were fever (range 56–71%), cough (range 41–79%), and shortness of breath (range 24–64%) [2]. Diarrhea, anosmia, and dysgeusia were more rarely reported. Because of these study designs, and the risk of underestimation in case of altered B-cell reconstitution, the rate of asymptomatic disease was rarely reported.

Healthcare-associated COVID-19 has been associated with poor outcomes in cancer patients [14] but data regarding hospital-acquired COVID-19 was mostly missing in HSCT recipients. However, in the study from Shah et al. [9], 45% of patients had a known exposure outside of the medical system.

In conclusion, HSCT recipients exhibit a high burden of comorbidities and similar clinical features almost similar to the general COVID population.

**KEY POINTS**

- HSCT recipients exhibit a high burden of comorbidities and COVID-19 clinical features almost similar to the general COVID population.
- HSCT recipients exhibit a protracted SARSCoV-2 shedding, prolonging duration of symptoms and promoting the generation of highly mutated viruses.
- HSCT recipients display poor COVID-19 outcomes, mainly driven by age, comorbidities, time from transplantation, and immunosuppression because of both treatments and underlying hematological malignancy.

| Table 1. Nine studies focusing on adult autologous and allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease-19 |
|--------------------------------------------------|
| **Author** |
| Belsky et al., meta-analysis |
| Camargo et al., USA |
| El Fakih et al., Middle East |
| **N** |
| Auto: 7, meta-analysis |
| Auto: 12, metanalysis |
| Auto: 39, meta-analysis |
| **Demographics** |
| Age range: 10.5–64 years |
| Age: 67 years (50–67) |
| Age: 35 years (16.3–38.9) |
| **Time from HSCT to COVID-19** |
| 77 days to 3 years |
| 21.5 months |
| 14.9 months (16.3–38.9) |
| **Time from COVID-19 to COVID-19-directed therapies** |
| 26 (7–64) |
| 26 (10–41.8) |
| 37 (14–116) |
| **Follow-up** |
| 7–64 days |
| 21.5 months |
| 14.9 months |
| **Common symptoms** |
| Fever: 56% |
| Cough: 56% |
| Dyspnea: 56% |
| Fever: 71% |
| Cough: 54% |
| Dyspnea: 33% |
| Fever: 56% |
| Cough: 41% |
| Dyspnea: 24% |
| **COVID-19-directed therapies** |
| Corticosteroids: 1% |
| Convalescent plasma: 1% |
| Tocilizumab: 1% |
| Remdesivir: 6% |
| IVIG: 7% |
| **Outcomes** |
| Severe COVID-19: 32.2% |
| ICU: 15% |
| MV: 15% |
| Secondary infection: 25% |
| Overall mortality: 4.4% |
| Severe COVID-19: 15% |
| ICU: 16% |
| MV: 10% |
| Overall mortality: 14% |
| **Risk factors** |
| Age ≥50 |
| Time from HSCT < 12 months |
| IS reduced/discontinued: 45% |
| Corticosteroids: 67% |
| Remdesivir: 60% |
| Convalescent plasma: 27% |
| Tocilizumab: 27% |
| Overall mortality: 4.4% |
| Author          | N     | Demographics | Common symptoms | Follow-up | Time from HSCT to COVID-19 | Viral shedding (days) | COVID-19 directed therapies | Outcomes                | Risk factors               |
|-----------------|-------|--------------|-----------------|-----------|---------------------------|-----------------------|---------------------------|---------------------------|---------------------------|
| Mushtaq et al., USA | Auto: 23, Allo: 32 | Age: 58 years [24–77] Male: 64% GVHD: 22% | Fever: 57% Cough: 65% Fatigue: 39% | 23 days (12–35) | 17 months (8–41) | 54 (14–131) | Remdesivir: 41% Convalescent plasma: 35% Corticosteroids: 22% Monoclonal antibodies: 19% Tocilizumab: 3% | Overall mortality: 16.3% Severe COVID-19: 28% ICU: 19% MV: 10% Secondary infection: 19% | Allogeneic HSCT IS Prior GvHD |
| Passamonti et al., Italy | Auto: 51, Allo: 31 | Age: 56.4 years [± 11.2] | Fever: 57% | 20 days (10–34) | 23 months (8–51) | Overall mortality: 34.1% | Overall mortality: 19% Empiric antibiotics: 14% | Progressive disease status | Underlying lymphoma |
| Sharma et al., USA | Auto: 134 | Age: 60 years [49–65] Male: 60% | Fever: 57% | 25 days (12–35) | Overall mortality: 22% Empiric antibiotics 5% | Overall mortality: 22% Secondary infection: 14% | Overall mortality: 22% | Age ≥ 50 Male sex Time from HSCT <12 months |
| Shah et al., USA | Auto: 37, Allo: 35 | Age: 62 years [25–78] Male: 64% GVHD: 17% | Cough: 65% Fever: 58% Fatigue: 39% | 23 days (14–35) | 25.6 months (11.6–52.8) | 28 (22–35) | Corticosteroids: 18% Convalescent plasma: 16% Tocilizumab 10% Remdesivir 4% | Overall mortality: 22% Secondary infection: 14% MV: 15% | Number of comorbidities Chest infiltrates Neutropenia |
| Varma et al., USA | Auto: 14, Allo: 20 | Age: 57 [24–76] Male: 65% GVHD: 26% | Fever: 71% Cough: 79% Dyspnea: 64% | 17.4 months (1–248.7) | IS reduced/discontinued: <1% Hydroxychloroquine: 44% Tocilizumab: 18% Remdesivir: 15% Convalescent plasma: 6% | Severe COVID-19: 41% Hospitalization: 74% ICU: 32% Mechanical ventilation: 24% Overall mortality: 21% | Age ≥ 60 BMI <20 Steroids at diagnosis of COVID-19 Time from HSCT <12 months Anemia Thrombopenia Lymphopenia |
| Xhaard et al., Europe | Allo: 54 | Age: 55 years Male: 57.4 | Fever: 72% Cough: 44.4% | 15.6 months (0–108) | Corticosteroids: 25.9% | Overall mortality: 25.9% ICU: 24.1% | | | |

Allo, allogeneic HSCT; auto, autologous HSCT; GVHD, graft-versus-host disease; HSCT, hematopoietic stem-cell transplantation; IS, immunosuppressants; MV, mechanical ventilation.
features to those reported in the general population and in other immunocompromised patients, suggesting a common host response to SARS-CoV-2 infection [2**,4].

LABORATORY EVALUATIONS AND PROTRACTED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SHEDDING IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

As reported for other immunocompromised patients (solid organ transplantation (SOT), solid tumors) [2**], most HSCT recipients displayed lymphopenia at the time of infection, while median leukocyte and neutrophil counts were within the normal range [2**,6,7,9,10–12,15]. In the series from Shah et al. [9*], COVID-19 was associated with a reduction in all lymphocyte subsets, not only including CD4 and CD8 T cells but also B lymphocytes and natural killers. Whenever reported, inflammatory markers, such as ferritin, C-reactive protein, and IL-6 were elevated [6,7,9,12,15], whereas renal and hepatic functions were rarely provided.

Data regarding chest radiography and computed tomography (CT) was scarce but most of HSCT patients exhibited bilateral infiltrates [6**,10,11,15]. In the study from Xhard et al., the central review of CT scans showed that atypical lesions were not rare, suggesting that COVID-19 should not be ruled out on the sole basis of radiological findings in HSCT recipients [11].

Nasal swab was the predominant method of COVID-19 diagnosis. Four studies provided data suggesting a consistent protracted viral shedding in HSCT patients [6**,7,9,12]. The median shedding time among HSCT patients with at least two consecutive positive tests ranged from 26 to 54 days. It has been reported that some HSCT patients may shed viable SARS-CoV-2 for at least 2 months, arguing for longer periods of isolation in such immunocompromised patients [16]. Protracted COVID-19 disease in immunocompromised patients relying on altered B-cell and T-cell immune responses could favor the generation of highly mutated viruses [17]. Further studies are needed to identify the HSCT-related immune determinants of COVID-19-shedding duration.

HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS EXHIBIT POOR CORONAVIRUS DISEASE 2019 OUTCOMES

In HSCT patients, estimated pooled prevalence of severe COVID-19, overall mortality, and ICU admission ranged from 15 to 41%, from 4.4 to 34%, and from 16 to 32%, respectively. However, there is no specific data focusing on outcomes among HSCT patients with COVID-19 requiring critical care. Mechanical ventilation was provided in 10–25% of the patients. These outcomes should be interpreted in light of the pandemic context, knowing that most of HSCT patients were not considered eligible for critical care.

In the largest series reported by Sharma et al., severe COVID-19 requiring mechanical ventilation occurred in 15% of 184 allogeneic HSCT recipients and 13% of 134 autologous HSCT recipients. The mortality of mechanically ventilated patients was not provided. The day-30 all-cause mortality was 22% for allogeneic HSCT recipients and 19% for autologous HSCT recipients. Importantly there was no association between survival and the type of transplantation [8**].

Despite an important heterogeneity between studies, these findings suggest a higher mortality among HSCT recipients with COVID-19 compared with the general population. In contrast, favorable outcomes reported by few studies seems attributable to highly selected population of HSCT recipients [12,18].

Ventilator-associated pneumonia and invasive fungal infections have emerged as important causes of morbidity and mortality in HSCT recipients [19,20]. In studies focusing on HSCT recipients with COVID-19, documented secondary infections were uncommon, including in patients under corticosteroids or tocilizumab [6**,7,8**,9,15]. Whenever reported, concurrent infections included ventilator-associated pneumonia, bacteremia, cytomegalovirus and herpes viremia, and aspergillus pneumonia [6**,7,9*].

However, proportions of HSCT recipients receiving empiric antibiotics could reach 80% among hospitalized patients, suggesting a high level of inappropriate anti-biotherapy [15]. In our institution, antibiotics are prescribed only in HSCT recipients with clinically or radiologically suspected superimposed bacterial infection or in those with febrile neutropenia.

UNCERTAIN HEMATOLOGICAL OUTCOMES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION POSTCORONAVIRUS DISEASE 2019

In SOT recipients, both patient and graft survival need to be taken account. Similarly, given the high prevalence of lymphopenia at the time of diagnosis, the potential need for immunosuppression tapering or discontinuation, the role of viral infections in altering the immune reconstitution and promoting GVHD,
Coronavirus Disease 2019 in hematopoietic stem cell recipients

Lafarge et al.

Determinants of Disease Severity in Hematopoietic Stem Cell Transplantation Recipients with Coronavirus Disease 2019

The baseline risk factors associated with HSCT recipients COVID-19 mortality were: older age [7,8,10], male sex [8*], number of comorbidities [9*], time from HSCT to COVID-19 infection less than 12 months [7,8,10,12], the use of steroids or at least two immunosuppressants [2*,6*,7,10], prior GVHD [6*], progressive disease status [4], and cytopenia [2*,9,10].

The association between COVID-19 mortality and older age, male sex, progressive malignancy, and baseline lymphopenia has already been demonstrated in the general population [1,4]. It is, thus particularly challenging to distinguish the relative contribution of HSCT immune dysregulation and its related complications on COVID-19 prognosis.

Risk factors, such as time from HSCT, use of immunosuppressive drugs, and active GVHD emphasize the burden of both procedure and drug-induced immunosuppression during the first months after HSCT. The impact of recent chemotherapy on COVID-19 prognosis in cancer patients remains controversial [21,22]. Interestingly, in the meta-analysis performed by Liu et al. [22], mortality was associated with recent chemotherapy in patients with hematological (RR 2.68, 1.90–3.78) but not with solid cancer.

Last, in most published studies focusing on HSCT and COVID-19, autologous and allogeneic HSCT recipients displayed similar short-term mortality rates. In contrast, in the single-center prospective study published by Mushtaq et al. after a median follow-up of 6.1 months, the mortality rate was higher in allogeneic HSCT recipients in comparison with autologous HSCT patients (28 and 16%, respectively). In this cohort, allogeneic HSCT was an independent predictor of COVID-19 severity [odds ratio 3.6; 95% confidence interval (CI) 1.2–10.8] [6*].

Coronavirus Disease 2019-Directed Therapies and Vaccination Need to Be Evaluated in Hematopoietic Stem Cell Transplantation Patients

COVID-19 clinical management algorithms and healthcare resources varied considerably depending on countries and pandemic waves. Thus, a careful critical review of therapeutic management in HSCT recipients with COVID-19 is hampered by the number of patients and the heterogeneity between studies and centers.

In most of patients, no specific treatment was described. In the series reported by Sharma et al. HSCT recipients with moderate or severe COVID-19 were more likely to receive COVID-19-directed therapies, such as corticosteroids, remdesivir, convalescent plasma, tocilizumab. The need for mechanical ventilation ranged from 10 to 25% but data regarding organ support were not routinely reported [8*]. In a variable proportion of HSCT patients across studies, therapeutic immunosuppression was reduced or discontinued.

Dexamethasone is now standard of care for patients with hypoxemia in COVID-19 pneumonia [23]. The efficacy of other directed therapies remains debated. Convalescent plasma might have a beneficial role for HSCT recipients without antibody response because of B-cell aplasia. In our institution, immunosuppressants are not systematically discontinued in HSCT patients with COVID-19.

The efficacy of SARS-CoV-2 mRNA vaccines has been successfully demonstrated in healthy populations [24]. A recent single-center cohort study reported a high response rate of 83% in allogeneic HSCT recipients after two doses of Pfizer-BioNTech COVID-19 vaccine [25*]. However, the efficacy to...
prevent severe COVID-19 in HSCT recipients needs to be confirmed. In this regard, a Blood and Marrow Transplant Clinical Trials Network study is currently investigating SARS-CoV-2 vaccine immunogenicity in HCT recipients [26].

DISCUSSION
This review summarizes COVID-19 features and outcomes in autologous and allogeneic HSCT recipients (Fig. 1). The interpretation of the emerging literature is limited by the heterogeneity between studies (pandemic time-period, geography, hematological malignancies, time from HSCT, age, ICU resources, proportion of outpatients), the short-term outcomes, the limited samples, the lack of transplant-related outcomes, and the retrospective design of these studies. Last, it should be noted that, in the context of overwhelmed health system because of the pandemic, most of HSCT patients were not considered eligible for critical care (including mechanical ventilation, extracorporeal membrane oxygenation support, ICU admission).

Further studies are warranted to analyze outcomes of HSCT patients admitted in ICU, determine the proper impact of HSCT-related immune disorders on COVID-19 outcomes, and evaluate directed therapeutic strategies, such as convalescent plasma in this high-risk population.

CONCLUSION
Available data suggest that HSCT recipients exhibit a high burden of comorbidities and COVID-19
clinical features similar to the general population. Furthermore, HSCT recipients exhibit a protracted SARS-CoV-2 shedding with prolonged symptoms and high risk of highly mutated viruses. Last, most studies report a higher COVID-19 mortality in HSCT recipients, mainly driven by age, comorbidities, time from transplantation, and immunosuppression because of both treatments and underlying hematological malignancy.

Taken together, these findings emphasize the need for more rigorous surveillance and preemptive measures for all HSCT recipients.

Acknowledgements
None.

Financial support and sponsorship
None.

Conflicts of interest
There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been highlighted as:
= of special interest
= of outstanding interest

1. Fung Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med 2020; 201:1380 –1388.
2. Belsky JA, Tullius BP, Lamb MG, et al. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant recipients. J Infect 2021; 82:329 –338.

In this first systematic review evaluating COVID-19 phenotype and outcomes in immunocompromised patients and comparing them to the general population, Belsky et al. identify poor COVID-19 outcomes, mainly driven by a higher comorbidity burden.

3. Mirouse A, Darmon M, Zafrañ L, et al. Impact of immunosuppression on mortality in critically ill COVID-19 patients. Br J Haematol 2020; 191:394 –395.
4. Passamonte F, Cattaneo C, Arcaini L, et al. ITA-HEMOV-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020; 7:e737 –e745.
5. ElGohary GM, Hashmi S, Styczynski J, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2020. S1658-3876(20)30122-9. [Epub ahead of print]
6. Mushaqh MU, Shahzad M, Chaudhary SG, et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients. Transplant Cell Ther 2021; 27:796e1 –796e7.

In this single-center prospective study with a median follow-up of 6 months, the mortality rate was 16% in all patients and 28% in allogeneic HSCT recipients. Among allogeneic HSCT recipients, 5 (16%) developed subsequent pulmonary chronic GVHD necessitating systemic steroids and additional IST. Significant predictors of COVID-19 severity included allogeneic HSCT, history of grade II/IV acute GVHD, and concurrent immunosuppressive drugs.

7. Camargo JP, Mendoza MA, Lin R, et al. Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy. Transpl Infect Dis Off J Transplant Soc 2021; 23:e13625.

8. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in hematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol 2021; 8:e185 –e183.

Three hundred and eighteen HSCT recipients diagnosed with COVID-19 were included in this retrospective study. At 30 days after the diagnosis of COVID-19, overall survival was 68% for recipients of allogeneic HSCT and 87% for recipients of autologous HSCT. Age 50 years or older, male sex, and development of COVID-19 within 12 months of transplantation were associated with a higher risk of mortality among allogeneic HSCT recipients.

9. Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest 2020; 130:6656 –6667.

This retrospective study provides preliminary insights into the lymphocyte populations that are key for the antiviral response and immune reconstitution. Immune profiling reveals reductions and rapid recovery in lymphocyte populations across lymphocyte subsets. Antibody responses were seen in a subset of patients.

10. Varma A, Kossii S, Ustun G, et al. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia 2020; 34:2809 –2812.

11. Xhaard A, Xhaard C, D’Aveni M, et al. Risk factors for a severe form of COVID-19 after allogeneic hematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Therapie cellulaire (SFGM-TC) multicentre cohort study. Br J Haematol 2021; 192:e121 –e124.

12. El Fakih R, Haroon A, Alfraih F, et al. Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East. Bone Marrow Transplant 2021; 56:2144 –2151.

13. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med 2021; 47:60 –73.

14. Elkrief A, Desliets A, Papnek N, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study. Eur J Cancer Off Engl 1990 2020; 139:181 –187.
15. Kanellopoulos A, Ahmed MZ, Kishore B, et al. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience. Br J Haematol 2020; 190:e67 –e70.

16. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 2020; 383:2586 –2588.

17. Cho B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020; 383:2291 –2293.

18. Lupo-Stanghellini MT, Xue E, Mastaglio S, et al. COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome. Bone Marrow Transplant 2021; 56:2312 –2315.

19. Aguilar-Guisado M, Jimenez-Jambrina M, Espigado I, et al. Spanish Network for Research in Infectious Diseases. Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study. Clin Transplant 2021; 25:E629 –E638.

20. Wang J, Zhou M, Xu JY, et al. Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: a systematic review and network meta-analysis. JAMA Netw Open 2020; 3:e2017652.

21. Song K, Gong H, Xu B, et al. Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: a multicenter study. Cancer 2021; 127:437 –448.

22. Liu H, Yang D, Chen X, et al. Effect of antiviral treatment on cancer patients with COVID-19: A systematic review and meta-analysis. Cancer Med 2020; 10:1043 –1056.

23. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Desamethasone in hospitalized patients with COVID-19 — preliminary report. N Engl J Med 2020; 384:693 –704.

24. Polack FP, Thomas SJ, Kitchin N, et al., C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020; 383:2603 –2615.

25. Le Bourgeois A, Coste-Burel M, Guillaume T, et al. Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplantation. JAMA Netw Open 2021; 4:e2126344.

This small observational cohort study examines safety and antibody responses after BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplantation. JAMA Netw Open 2021; 4:e2126344.

26. BMCTCN website [Internet]. [cited 28 September 2021]. Available at: https://web.emmes.com/study/bmt3f/protocol/2101_protocol/2101_protocol.html.